Joseph Wu

12.1k total citations · 2 hit papers
236 papers, 6.9k citations indexed

About

Joseph Wu is a scholar working on Molecular Biology, Geriatrics and Gerontology and Genetics. According to data from OpenAlex, Joseph Wu has authored 236 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Molecular Biology, 40 papers in Geriatrics and Gerontology and 37 papers in Genetics. Recurrent topics in Joseph Wu's work include Sirtuins and Resveratrol in Medicine (40 papers), Inflammatory Bowel Disease (29 papers) and Autoimmune and Inflammatory Disorders Research (22 papers). Joseph Wu is often cited by papers focused on Sirtuins and Resveratrol in Medicine (40 papers), Inflammatory Bowel Disease (29 papers) and Autoimmune and Inflammatory Disorders Research (22 papers). Joseph Wu collaborates with scholars based in United States, Canada and United Kingdom. Joseph Wu's co-authors include Tze‐chen Hsieh, Zbigniew Darżynkiewicz, T C Hsieh, Yuanzhu Huang, Anna M. Dipietrantonio, Tze-chen Hsieh, Robert J. Suhadolnik, Jiangang Zou, Zhirong Wang and Juan Gao and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Joseph Wu

221 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

2021 159 citations Dona Fleishaker, Joseph Wu et al. profile →
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

2022 123 citations Ivana Vranić, Joseph Wu et al. profile →

Peers

Countries citing papers authored by Joseph Wu

Since Specialization

Citations

This map shows the geographic impact of Joseph Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Wu more than expected).

Fields of papers citing papers by Joseph Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Wu. The network helps show where Joseph Wu may publish in the future.

Co-authorship network of co-authors of Joseph Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Wu. A scholar is included among the top collaborators of Joseph Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Wu. Joseph Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Revealing the Mechanisms of Shikonin Against Diabetic Wounds: A Combined Network Pharmacology and In Vitro Investigation 2025 ·Journal of Diabetes Research ·Meng Tian, Joseph Wu, (unknown), (unknown), (unknown), Xiang Li, Mingzhu Li, Xiaofeng Ding, (unknown)	1
2	DOP018 Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programme 2025 ·Journal of Crohn s and Colitis ·Séverine Vermeire, David T. Rubin, Miguel Regueiro, Ken Takeuchi, Alissa Walsh, Paulo Gustavo Kotze, (unknown), Martina Goetsch, (unknown), Joseph Wu, (unknown), (unknown), (unknown), Silvio Danese	0
3	Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program 2025 ·Inflammatory Bowel Diseases ·Bruce E. Sands, Marla C. Dubinsky, Paulo Gustavo Kotze, Séverine Vermeire, Remo Panaccione, Millie D. Long, John Woolcott, Joseph Wu, Aoibhinn McDonnell, Martina Goetsch, Eustratios Bananis, Andrés Yarur	0
4	P113 Maintenance of week 12 response through week 52 with etrasimod in patients with ulcerative colitis in ELEVATE UC 52 2024 ·Poster presentations ·(unknown), Séverine Vermeire, Marla Dubinsky, Brian Feagan, Remo Panaccione, Vipul Jairath, Andrés Yarur, Michael Chiorean, Julián Panés, Martina Goetsch, (unknown), Joseph Wu, Subrata Ghosh, (unknown)	0
5	Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme 2024 ·Journal of Crohn s and Colitis ·Laurent Peyrin‐Biroulet, Marla C. Dubinsky, Bruce E. Sands, Julián Panés, (unknown), Walter Reinisch, Brian G. Feagan, Silvio Danese, Andrés Yarur, Geert D’Haens, Martina Goetsch, Karolina Wosik, Michael J. Keating, (unknown), Joseph Wu, Irene Modesto, Aoibhinn McDonnell, (unknown), Séverine Vermeire	16
6	716 PREGNANCY OUTCOMES AFTER MATERNAL OR PATERNAL EXPOSURE IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM 2024 ·Gastroenterology ·Uma Mahadevan, María Chaparro, (unknown), (unknown), Xiang Guo, Joseph Wu, Ivana Vranić, (unknown), Marla C. Dubinsky	4
7	The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program 2024 ·Inflammatory Bowel Diseases ·Vipul Jairath, David T. Rubin, Bram Verstockt, Ayhan Hilmi Çekın, María T. Abreu, Charlie W. Lees, (unknown), John Woolcott, Catherine Crosby, Joseph Wu, Abhishek Bhattacharjee, David C. Herman, Guibao Gu, Britta Siegmund	2
8	Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials 2024 ·Journal of Crohn s and Colitis ·Séverine Vermeire, Bruce E. Sands, Laurent Peyrin‐Biroulet, Geert D’Haens, Julián Panés, Andrés Yarur, Douglas C. Wolf, Timothy E. Ritter, Stefan Schreiber, John Woolcott, (unknown), Michael J. Keating, (unknown), Joseph Wu, Michael Chiorean, Filip Baert, Marla C. Dubinsky, Martina Goetsch, Silvio Danese, Brian G. Feagan	5
9	P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials 2023 ·Journal of Crohn s and Colitis ·Laurent Peyrin‐Biroulet, Marla C. Dubinsky, B E Sands, Julián Panés, S Schreiber, Walter Reinisch, B G Feagan, Silvio Danese, Andrés Yarur, Geert D’Haens, (unknown), (unknown), Joseph Wu, Irene Modesto, (unknown), (unknown), (unknown), Séverine Vermeire	4
10	P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials 2023 ·Journal of Crohn s and Colitis ·Séverine Vermeire, Laurent Peyrin‐Biroulet, Julián Panés, Miguel Regueiro, Paulo Gustavo Kotze, (unknown), (unknown), (unknown), Joseph Wu, (unknown), John Woolcott, Silvio Danese	9
11	P476 Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme 2023 ·Journal of Crohn s and Colitis ·Séverine Vermeire, Andrés Yarur, David T. Rubin, Marla C. Dubinsky, Miguel Regueiro, Peter M. Irving, Laurent Peyrin‐Biroulet, (unknown), (unknown), Joseph Wu, Irene Modesto, (unknown), (unknown), (unknown), (unknown)	3
12	Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial 2023 ·Rheumatology and Therapy ·Mikkel Østergaard, Joseph Wu, Lara Fallon, Sarah P. Sherlock, Cunshan Wang, Dona Fleishaker, Keith S. Kanik, Walter P. Maksymowych	2
13	Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study 2021 ·The Lancet ·Peter Nash, Laura C. Coates, Dona Fleishaker, Alan Kivitz, (unknown), Dafna D. Gladman, Oliver FitzGerald, (unknown), Joseph Wu, (unknown), Sujatha Menon, Lara Fallon, Keith S. Kanik	0
14	Elucidating the Inhibitory Effect of Resveratrol and Its Structural Analogs on Selected Nucleotide-Related Enzymes 2020 ·Biomolecules ·Yifei Wu, Tze‐chen Hsieh, Joseph Wu, Xiaoxiao Wang, (unknown), (unknown), (unknown), Lei Lou, Zhong‐Ru Xie	12
15	Tofacitinib Improves Composite Endpoint Measures of Disease in Patients with Psoriatic Arthritis 2017 ·Oxford University Research Archive (ORA) (University of Oxford) ·Philip Helliwell, Laura C. Coates, Oliver FitzGerald, Peter Nash, Enrique R. Soriano, M. Elaine Husni, Ming‐Ann Hsu, Keith S. Kanik, Thijs Hendrikx, Joseph Wu, Elizabeth M. Kudlacz	3
16	Rate Of Malignant Transformation In High Risk Et During 5 Years Of Follow-Up Of Cytoreductive Therapy 2016 ·Haematologica ·Gunnar Birgegård, Yasin Folkvaljon, Hans Garmo, Carlos Besses, Martin Grießhammer, L Gugliotta, Claire Harrison, (unknown), Joseph Wu, (unknown), Jean‐Jacques Kiladjian	1
17	Resveratrol Prevents Monocrotaline-Induced Pulmonary Hypertension in Rats 2009 ·Hypertension ·Anna Csiszár, Nazar Labinskyy, Susan C. Olson, John T. Pinto, Sachin A. Gupte, Joseph Wu, Furong Hu, Praveen Ballabh, Andrej Podlutsky, György Losonczy, Rafael de Cabo, Rajamma Mathew, Michael S. Wolin, Zoltán Ungvári	174
18	Effects of Extracts of Coriolus versicolor (I'm-Yunity ^™ ) on Cell-Cycle Progression and Expression of Interleukins-1β,-6, and -8 in Promyelocytic HL-60 Leukemic Cells and Mitogenically Stimulated and Nonstimulated Human Lymphocytes 2002 ·The Journal of Alternative and Complementary Medicine ·Tze‐chen Hsieh, Jan Kunicki, Zbigniew Darżynkiewicz, Joseph Wu	50
19	DIAGNOSTIC VALUE OF THE DETERMINATION OF AN INTERFERON-INDUCED ENZYME ACTIVITY: DECREASED 2′,5′-OLIGOADENYLATE DEPENDENT BINDING PROTEIN ACTIVITY IN AIDS PATIENT LYMPHOCYTES 1986 ·PubMed ·Joseph Wu, Jen Wei Chiao, Shlomo Maayan	8
20	The Effect of Ammonium Ion on the Induction of (2'-5')-(A) _n Synthetase and (2'-5')-(A) _n -Dependent Endoribonuclease Activities by Interferon in Mouse BALB/C 3T3 Cells 1986 ·Journal of Interferon Research ·Joseph Wu, (unknown), (unknown), (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact